• Early Stage/Localized Disease/Ablative Therapies
  Keywords: Neoadjuvant/ Adjuvant therapies, Early Stage, Minimally Invasive Surgery, Stage I, Stage II, Stereotactic Body Radiation Therapy
• Global Health
  Keywords: Patterns of care, lower socioeconomic countries global health
• Health Services Research/Health Economics
  Keywords: Health Policy, Cost Effectiveness, Quality of Care, Healthcare Access, Qualitative Research, Real-World Data, Observational Cohort Studies, Disease Registries And Databases, Artificial Intelligence, Machine Learning
• Immuno-Biology and Novel Immunotherapeutics (Phase I and Translational)
  Keywords: Tumor Micro-environment, Bi-specific Ab, Vaccine Therapy, Cellular Therapy, Chimeric Antigen Receptors, Viroimmunotherapy, Cytokine Therapy, Translational Research, Check-Point Blockade Beyond PD-1/L1
• Immunotherapy (Phase II/III Trials)
  Keywords: Phase II and III Clinical Trials, Immune Checkpoint Inhibitors, Randomised Controlled Trials, Biomarkers
• Liquid Biopsy and Other Non-invasive Diagnostic Modalities
  Keywords: Circulating Tumor Cells, Circulating Tumor DNA, Cell Free DNA, Circulating Cell-Free Noncoding RNAs, Circulating Exosomes, Liquid Biopsy, pleural effusion assays, urine based testing
• Locally Advanced NSCLC
  Keywords: Chemoradiation, immunotherapy, surgical resection, tri-modality therapy,   neoadjuvant
• Management of lung cancer in the era of COVID 19
  Keywords: Impact on care, complications, risk factors, impact on diagnosis and treatment
• Mesothelioma, Thymoma and Other Thoracic Malignancies
  Keywords: Malignant Mesothelioma, Thymoma, Thymic Carcinoma, Thymic Epithelial Tumors, Oesophageal Cancer
• Multimodality Management of Advanced Lung Cancer
  Keywords: Stereotactic Body Radiotherapy, Local Ablative Therapy, metastectomy, oligo-progression
• Novel Therapeutics and Targeted Therapies
  Keywords: novel cytotoxics, phase I, pre-clinical, anti-body conjugates
• Nursing and Allied Health Professionals
  Keywords: Rehabilitation, Physiotherapy, Survivorship Care
• Palliative and Supportive Care
  Keywords: Palliative care, Decision-making, Decision Support Techniques, Ethics, Quality of Life, Integrative care
• Patient Advocacy 
  Keywords: Survivorship, Advocacy, Community Outreach, Patient-driven Research, Advocacy Foundations, Patient Advocacy, Patient Reported Outcomes, Lung Cancer Stigma
• Predicative Tumor Based Assays/Biomarkers/Pathology
  Keywords: tumor microenvironment, IHC. FISH, NGS, tissue diagnostics, novel tumor
• Risk Reduction and Tobacco Control
  Keywords: Tobacco Control Policy, Tobacco Prevention Patient, Framework Convention on Tobacco Control, Smoking Cessation, Radon, Bio Mass, Environmental
• Screening and Early Detection
  Keywords: Screening, Early Detection, Low Dose Spiral CT Scan, Early Diagnosis, Exhaled Air, Pulmonary Nodule, GGO, Biomarkers For Early Detection, Risk Models, Nodule Evaluation, Artificial Intelligence For Early Detection, Radiomics
• Small Cell Lung Cancer/NET
  Keywords: Small Cell Lung Cancer, Neuroendocrine Tumours, Atypical Carcinoid
• Staging/Pulmonary Medicine
  Keywords: Staging, Tumor Size Characteristics, Node Characteristics, Metastatic Characteristics, IASLC Staging System
• Tumor Biology and Systems Biology – Basic and Translational Science
  Keywords: Tumor Biology, Mouse Models, Basic Science, Translational Science, Bioinformatics, Transcriptomics and other novel omics,

 

Dear Colleagues and Friends, Sponsors and Exhibitors,

Considering the ongoing concerns caused by COVID-19, the IASLC decided to transition all of its 2021 live conferences to worldwide virtual events, including the next World Conference on Lung Cancer 2021 so you can experience the Conference from the comfort and safety of your home or office.

The IASLC continues to monitor the situation on an ongoing basis. If public health circumstances allow, the IASLC may also offer in-person opportunities if feasible. Our primary goal is to ensure that educational and scientific content is available to all interested participants, while protecting the health and well-being of attendees and faculty.

We are working on a new virtual experience that will be both, interesting and engaging. Join us virtually from September 8 – 14, 2021. We are planning for more but shorter days full of practice-changing science.

The IASLC is committed to offering quality experiences that continue to provide opportunities for attendee engagement that have been a hallmark of the IASLC’s in-person conferences. The IASLC will continue to deliver on its fundamental mission by bringing critical education in all aspects of thoracic cancer to the widest possible audience. In addition to Plenary and Educational Sessions, the program will feature a full day of audience and regional targeted workshops.

We recognize that many of our global and multidisciplinary members and meeting attendees are healthcare workers who are on the front line of studying, diagnosing and treating lung cancer. We want to express our gratitude and admiration to you and to all health care professionals working in incredibly difficult circumstances to contain this outbreak and prevent further loss of life.

We hope to see you online or perhaps in person from September 8 – 14. Even if we are physically apart, we are still together as a community, connected by a shared passion for conquering thoracic cancers and malignancies worldwide and for the best outcomes for our patients.

Sincerly,

David Harpole, IASLC WCLC 2021 Conference President

Kristin Higgins, IASLC WCLC 2021 Conference Co-Chair

Thomas A. Stinchcombe, IASLC WCLC 2021 Conference Co-Chair